In recent years, TAVR has been increasingly used; however, when it comes to younger, lower risk patients, its use is still challenged. In this context, there is limited information and we lack randomized studies on “real world” cohorts. The DEDICATE randomized 1.414 patients over 65 with severe symptomatic aortic stenosis. 701 of these patients received<a href="https://solaci.org/en/2024/04/11/acc-2024-dedicate-trial-transcatheter-or-surgical-treatment-of-aortic-valve-stenosis/" title="Read more" >...</a>
Temporal Trends in Transcatheter Aortic Valve Replacement for Isolated Severe Aortic Stenosis
A study by the Northern New England Cardiovascular Disease Group Consortium recently published online identified all patients with aortic valve stenosis treated with surgical or transcatheter aortic valve replacement between 2016 and 2022 in Maine, New Hampshire, and Vermont (USA). These patients were divided for analysis into three age groups: under 65 years old, 65<a href="https://solaci.org/en/2024/04/11/temporal-trends-in-transcatheter-aortic-valve-replacement-for-isolated-severe-aortic-stenosis/" title="Read more" >...</a>
Tricuspid Valve Transcatheter Edge-to-Edge Repair in the “Real World”
Tricuspid valve transcatheter edge-to-edge repair (T-TEER) is currently under development, with an increasing number of conducted procedures. While the TRILUMINATE Study did not reveal benefit regarding major events, it did show improvements in quality of life. In the real world, we encounter numerous patients who do not meet the study criteria but still experience symptoms<a href="https://solaci.org/en/2024/03/08/tricuspid-valve-transcatheter-edge-to-edge-repair-in-the-real-world/" title="Read more" >...</a>
Benefit of Cusp overlap method for self‐expanding transcatheter aortic valves
The need for permanent pacemaker implantation (PPM) continues to be one of the main challenges in TAVR, especially with self-expanding valves, with a pacemaker implantation rate that varies between 17.5% and 30% in large randomized studies, vs. 4% to 6.5% with self-expanding valves. Therefore, in an attempt to prevent the need for PPM implantation, the<a href="https://solaci.org/en/2024/02/02/benefit-of-cusp-overlap-method-for-self%e2%80%90expanding-transcatheter-aortic-valves/" title="Read more" >...</a>
Promising Results of Transcatheter Mitral Valve Replacement in Bioprosthesis Failure
Failure of a mitral bioprosthesis always poses a challenge regarding decision-making, especially when dealing with elderly patients with multiple risk factors. The scenario is worsened by the high risk associated with a new sternotomy and the significant impact of undergoing new surgery. Transcatheter mitral valve-in-valve (TMViV) replacement is emerging as a valid strategy in the<a href="https://solaci.org/en/2024/02/01/promising-results-of-transcatheter-mitral-valve-replacement-in-bioprosthesis-failure/" title="Read more" >...</a>
Transcatheter Mitral Valve Replacement: DOAC or VKA?
Severe mitral disease is common and currently constitutes a frequent cause of hospitalization and death. While surgery is the treatment of choice, transcatheter mitral valve replacement (TMVR) emerges as a valid alternative in cases of bioprosthesis failure, ring malfunction, or severe mitral annular calcification (MAC). Furthermore, the latest medical guidelines support the recommendation of TMVR<a href="https://solaci.org/en/2024/01/26/transcatheter-mitral-valve-replacement-doac-or-vka/" title="Read more" >...</a>
Use of Apixaban and Post TAVR Valve Thrombosis
TAVR can be associated to early valve thrombosis, characterized by thrombi formation near or attached to the prosthetic valve, with or without valve dysfunction. This dysfunction is associated with increased leaf thickening and reduced leaflet motion, as well as reduced orifice area or increased transvalvular gradient. Triggered multislice CT allows dynamic valve assessment and thrombosis<a href="https://solaci.org/en/2024/01/25/use-of-apixaban-and-post-tavr-valve-thrombosis/" title="Read more" >...</a>
Transcatheter Pulmonary Valve Replacement | SOLACI-SBHCI 2023 – International Live Case
✔️ SOLACI-SBHCI 2023 – International Live Case | Transcatheter pulmonary valve replacement. ✔️ Site: Medicine, Doha, Qatar. ✔️ August 3, 2023, Arpoador Room, Windsor Oceánico.
TAVI for Pure Aortic Valve Regurgitation Using a Newself-Expanding Technology | SOLACI-SBHCI 2023
✔️ SOLACI-SBHCI 2023 – International Live Case | TAVI for Pure Aortic Valve Regurgitation Using a Newself-Expanding Technology ✔️ Site: Nanjing First Hospital, Nanjing, China ✔️ August 4, 2023, Copacabana Room, Windsor Oceánico
Transcatheter Pulmonary Valve Replacement | SOLACI-SBHCI 2023 – International Edited Case
✔️ SOLACI-SBHCI 2023 – International Live Case | Transcatheter pulmonary valve replacement. ✔️ Site: Union Hospital – Wuhan, China. ✔️ August 4, 2023, Arpoador Room, Windsor Oceánico.